Atosiban


Concise Prescribing Info
Indications/Uses
Premature labour.
Dosage/Direction for Use
Adult : IV Initial: 6.75 mg bolus (as 7.5 mg/mL soln), immediately followed by continuous infusion (as 0.75 mg/mL soln) of 0.3 mg/min for 3 hr, then 0.1 mg/min for up to 45 hr. Total duration: ≤48 hr. Max: 330.75 mg.
Dosage Details
Intravenous
Premature labour
Adult: Initially, 6.75 mg bolus (as 7.5 mg/mL soln) over 1 min, immediately followed by continuous infusion (as 0.75 mg/mL soln) of 0.3 mg/min for 3 hr, then 0.1 mg/min for up to 45 hr. Total duration: ≤48 hr. Max: 330.75 mg.
Reconstitution
Soln for infusion: Withdraw 10 mL from a 100-mL bag of NaCl 0.9%, glucose 5% or Ringer’s lactate soln and replace w/ 10 mL of atosiban concentrate (using 2 vials of 37.5 mg/5 mL soln) to produce a final concentration of 0.75 mg/mL.
Contraindications
Gestational age <24 or >33 wk, premature rupture of membranes >30 wk of gestation, uterine haemorrhage requiring immediate delivery, eclampsia, severe pre-eclampsia, intra-uterine growth retardation w/ abnormal foetal heart rate, intra-uterine foetal death, suspected intra-uterine infection, placenta praevia, abruptio placentae.
Special Precautions
Patient w/ abnormal placental site, intra-uterine growth restriction, multiple pregnancy. Hepatic impairment. Lactation.
Adverse Reactions
Nausea, vomiting, headache, dizziness, flushes, tachycardia, hypotension, hyperglycaemia, inj site reactions; insomnia, pruritus, rash, pyrexia. Rarely, uterine haemorrhage and atony.
MonitoringParameters
Monitor uterine contractions and foetal heart rate during use, and blood loss after delivery.
Drug Interactions
Increased risk of pulmonary oedema w/ other tocolytic drugs (e.g. Ca channel blockers, betamimetics).
Action
Description: Atosiban, a synthetic oxytocin peptide analogue, is a competitive antagonist of oxytocin receptors. It suppresses uterine contractions by decreasing its frequency and the tone of uterine musculature. Additionally, it inhibits the effect of vasopressin.
Pharmacokinetics:
Distribution: Crosses the placenta and enters breast milk. Plasma protein binding: 46-48%.
Metabolism: Metabolised to 2 active metabolites.
Excretion: Via urine (small amount). Terminal half-life: 1.7 hr.
Storage
Store between 2-8°C. Protect from light.
ATC Classification
G02CX01 - atosiban ; Belongs to the class of other gynecologicals. Used to inhibit uncomplicated premature labour between 24 and 33 weeks of gestation.
References
Anon. Atosiban. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/10/2016.

Buckingham R (ed). Atosiban. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/10/2016.

Joint Formulary Committee. Atosiban. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/10/2016.

Disclaimer: This information is independently developed by MIMS based on Atosiban from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in